Anixa Biosciences, Inc. (ANIX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANIX Stock Price Chart Interactive Chart >
ANIX Price/Volume Stats
| Current price | $4.89 | 52-week high | $6.25 |
| Prev. close | $4.97 | 52-week low | $2.30 |
| Day low | $4.80 | Volume | 22,400 |
| Day high | $5.03 | Avg. volume | 81,991 |
| 50-day MA | $5.03 | Dividend yield | N/A |
| 200-day MA | $3.80 | Market Cap | 149.94M |
Anixa Biosciences, Inc. (ANIX) Company Bio
Anixa Biosciences, Inc., a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of cancer, which is based on the body's immune response to the presence of a malignancy. It is also developing a vaccine against triple negative breast cancer; and chimeric endocrine receptor T-cell technology focused on treating ovarian cancer. Anixa Biosciences, Inc. has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy technology; and with OntoChem GmbH to develop novel Covid-19 therapeutics. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.
Latest ANIX News From Around the Web
Below are the latest news stories about ANIXA BIOSCIENCES INC that investors may wish to consider to help them evaluate ANIX as an investment opportunity.
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer SymposiumAnixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining the design of its ongoing breast cancer vaccine trial on December 7, 2022, at the 2022 San Antonio Breast Cancer Symposium. |
Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer Institute, will Discuss Anixa Biosciences' Ovarian Cancer CAR-T TherapyAnixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia, Senior Member of the Immunology Department at Moffitt Cancer Center, has been invited to be the keynote speaker at Duke Cancer Institute's Immuno-Oncology Research Program Retreat on November 4, 2022. |
Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at Cleveland ClinicAnixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1b trial for its preventative breast cancer vaccine. The study is being conducted at Cleveland Clinic and will evaluate safety and monitor immune response. |
Anixa Biosciences (NASDAQ:ANIX) Is In A Strong Position To Grow Its BusinessEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual MeetingAnixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining its ovarian cancer CAR-T therapy trial at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting being held November 8-12, 2022. The presentation, titled "Phase I clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) i |
ANIX Price Returns
| 1-mo | -12.05% |
| 3-mo | 15.88% |
| 6-mo | 19.85% |
| 1-year | 58.25% |
| 3-year | 29.37% |
| 5-year | 102.07% |
| YTD | 64.65% |
| 2021 | -3.26% |
| 2020 | -6.40% |
| 2019 | -16.75% |
| 2018 | 66.95% |
| 2017 | -56.30% |
Continue Researching ANIX
Here are a few links from around the web to help you further your research on Anixa Biosciences Inc's stock as an investment opportunity:Anixa Biosciences Inc (ANIX) Stock Price | Nasdaq
Anixa Biosciences Inc (ANIX) Stock Quote, History and News - Yahoo Finance
Anixa Biosciences Inc (ANIX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...